

AMENDMENTS TO THE SPECIFICATION

Please enter the following amendment without prejudice or disclaimer.

In the Summary of the Invention which begins on page 2, line 25, please make the following amendment in paragraph 8 (the third paragraph added in the Preliminary Amendment filed September 20, 2002):

This invention further provides a method for identifying ~~an agonist or~~ an antagonist of a human endothelin receptor, comprising the steps of:

contacting a sample comprising human endothelin receptor having an affinity for endothelins 1 and 2, comprising an amino acid sequence from Asp at 1 to Asn at 407 of SEQ ID NO: 1, with a candidate compound; and
detecting binding of the candidate compound to the endothelin receptor.

Please delete paragraph 12 (the seventh paragraph added in the Preliminary Amendment filed September 20, 2002) which follows paragraph 11 as follows:

In another embodiment, the step of detecting comprises measuring a change in a current across the cell membrane.

~~In one embodiment, the current across the cell membrane increases, and the candidate compound is determined to be an agonist.~~

Please delete paragraph 20 (the fifteenth paragraph added in the Preliminary Amendment filed September 20, 2002) which follows paragraph 19 as follows:

In another embodiment, the step of detecting comprises measuring a change in a current across the cell membrane.

~~In one embodiment, the current across the cell membrane increases, and the target compound is an agonist.~~

Please delete paragraph 29 (the twenty-fourth paragraph added in the Preliminary Amendment filed September 20, 2002) which follows paragraph 28 as follows:

In another embodiment, the step of detecting comprises measuring a change in a current across the cell membrane.

~~In one embodiment, the current across the cell membrane increases, and the target compound is an agonist.~~

Please delete paragraph 37 (the thirty-second paragraph added in the Preliminary Amendment filed September 20, 2002) which follows paragraph 36 as follows:

In another embodiment, the step of detecting comprises measuring a change in a current across the cell membrane.

~~In one embodiment, the current across the cell membrane increases, the target compound is an agonist, and the condition is caused by a reduced endothelin receptor activity.~~

In the Brief Description of the Drawings which follows the Summary of the Invention, please make the following amendments in paragraphs 1 and 2 as follows:

Figure 1 shows DNA coding sequence and deduced amino acid sequence of an ET_A-receptor according to the present invention (SEQ ID NO:1).

Figure 2 shows DNA coding sequence and deduced amino acid sequence of an ET_B-receptor according to the present invention (SEQ ID NO:2).